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Background: JSOG-6 is used as a traditional medicine to relieve the symptoms associated with inflammation,
rheumatism, and osteoporosis in Korea. In the present study, we investigated the effects of JSOG-6 on bone loss
prevention both in in vitro and in vivo as well as its underlying mechanism of action.
Methods: Protection against bone loss was assessed in an ovariectomized (OVX) mouse model. Bone
microarchitecture was measured using a micro-computed tomography to detect the parameters of three-dimensional
structure of a trabecular bone. Serum biomarkers were also evaluated in an OVX-induced model. Osteoclasts derived
from mouse bone marrow cells (BMCs) and osteoblastic MC3T3-E1 cells were also employed to investigate the
mechanism of action.
Results: Oral administration of JSOG-6 significantly increased the bone mineral density (BMD) of the femur in OVX mice
in vivo. Especially, the reduced Tb.No (trabecular bone number) in the OVX group was significantly recovered by
JSOG-6 treatment. The serum levels of alkaline phosphatase (ALP), osteocalcin, C-terminal telopeptide, and
tartrate-resistant acid phosphatase, biomarkers of bone resorption, were significantly elevated in OVX mice, but
JSOG-6 effectively inhibited the increase in OVX mice. JSOG-6 was also found to enhance the osteoblastic
differentiation and maturation with the increase of the density and ALP activity, a marker of osteoblastic
differentiation, as well as calcium deposition, a marker of osteoblastic maturation in MC3T3-E1 cells. The effects
of JSOG-6 on osteoblastic differentiation were also associated in part with the increase of ALP and OPN mRNA
expressions and the decrease of RANKL mRNA expression in MC3T3-E1 cells.
Conclusions: The findings demonstrate that JSOG-6 induced protection against bone loss in OVX mice, and its
anti-osteoporotic property might be, in part, a function of the stimulation of osteoblast differentiation and the
inhibition of osteoclast formation. These findings suggest that JSOG-6 might be an applicable therapeutic
traditional medicine for the regulation of the osteoporotic response.
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Osteoporosis is an age-dependent metabolic bone disease
characterized by the decrease in bone mass, the deterior-
ation of bone tissue, and an increased risk of fractures
[1,2]. In the process of osteoporosis, the bone mineral
density (BMD) is decreased, bone microarchitecture is de-
teriorated, and a variety of proteins in bone are also* Correspondence: sklee61@snu.ac.kr
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modeling through bone resorption and bone formation by
osteoclasts and osteoblasts, respectively [3,4]. Indeed, bone
homeostasis depends on maintaining a balance between
the activities of bone-forming osteoblasts and bone-
resorbing osteoclasts [5,6], which is ultimately determined
by the proliferation and differentiation of progenitors of
these two bone-associated cells.
Osteoclasts are derived from hematopoietic cells within
the monocyte/macrophage lineage [7] and regulated by theLtd. This is an Open Access article distributed under the terms of the Creative
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ligand (RANKL) [8]. However, osteoblasts induce the
increase in bone mass by inhibiting the ability of osteo-
clasts. Osteoblasts also express RANKL and osteopro-
tegerin (OPG), a decoy receptor of RANKL, which are
essential factors regulating the formation and activation
of osteoclasts (osteoclastogenesis) [9,10]. Therefore, the
balance of RANKL and OPG mainly contributes to bone
remodeling because RANKL stimulates osteoclastogen-
esis, while OPG suppresses bone resorption [11]. Yet,
excessive osteoclastogenesis and defects in osteoblasto-
genesis are associated with bone diseases such as osteo-
porosis and rheumatoid arthritis [12].
JSOG-6 (named Bogangyeongol-hwan) consists of a mix-
ture of six crude drugs, and each drug has been widely used
in traditional medicine to treat various bone disorders such
as arthritis, degenerative disc disease and osteoporosis. Of
the six components of JSOG-6, Harpagophytum procum-
bens var. sublobatum (Engl.) Stapf, radix, called Devil’s claw,
is an herbal substance commonly used by patients with
osteoarthritis (OA). Anti-inflammatory activities of the
root extracts of H. procumbens var. sublobatum have
also been reported in various inflammation models
[13-15]. Another component of JSOG-6, Drynaria for-
tunei (Kunze ex Mett.) J. Sm., rhizome also showed an
anti-osteogenic effect in a bone-resorption model [16]
as well as anti-inflammatory properties [17]. Poria cocos
F.A.Wolf, sclerotium [18] and Rehmannia glutinosa
(Gaertn.) DC., radix [19] exhibited anti-inflammatory
effects. Furthermore, Panax ginseng C.A.Mey., radix
showed an anti-osteoporotic effect in an OVX rat model
[20]. These reported data suggest that JSOG-6 might
have the potential to alleviate the symptoms of bone
loss-associated diseases.
In the present study, we investigated the activities of
JSOG-6 in vitro and in in vivo bone-remodeling models
and examined its underlying molecular mechanism.Methods
Preparation of test samples
A mixture of six crude drugs (Harpagophytum procumbens
var. sublobatum (Engl.) Stapf, radix (120 g), Drynaria fortu-
nei (Kunze ex Mett.) J. Sm., rhizome (120 g), Equus asinus
L., gelatinized (120 g), Poria cocos F.A.Wolf, sclerotium
(120 g), Rehmannia glutinosa (Gaertn.) DC., radix (120 g),
and Panax ginseng C.A.Mey., radix (120 g)) was boiled in
tap water (10 L) for 6 h, and the extract was freeze-dried to
obtain the JSOG-6 extracts (259 g, 35.6%). The crude drugs
were purchased from an herbal market in Seoul, Korea,
and authenticated by Dr. S.H. Lee, Jaseng Hospital of
Korean Medicine in Seoul, Korea. Voucher specimens of
the plants used in this study were deposited in the herbar-
ium at Jaseng Hospital of Oriental Medicine.Animals
Female ICR mice (18–20 g, ~8 weeks old) were purchased
from Central Laboratory Animal Inc. (Seoul, Korea). Ani-
mals were housed under standard laboratory conditions
with free access to food and water. The temperature was
thermostatically regulated to 22°C ± 2°C, and a 12-hour
light/dark schedule was maintained. Prior to their use, they
were allowed one week for acclimatization within the work
area environment. All animal experiments were carried out
in accordance with the Institutional Animal Care and Use
Committee Guidelines of Ewha Womans University (per-
mission number: EWHA2010-2-07).
At 9 weeks of age, mice were bilaterally OVX, and 8 mice
were Sham-operated (Sham). After 1 week of recovery from
surgery, the OVX mice were randomly divided into 5
groups of 8 mice per group (OVX control, 17β-estradiol
(E2, 20 μg/kg), and JSOG-6 (50, 150, or 450 mg/kg)).
JSOG-6 was orally administered in distilled water (0.3 mL)
for 12 weeks, and the same volume of distilled water was
used in the Sham- and OVX control groups. After 12 weeks
of treatment, the animals were sacrificed, and blood sam-
ples were collected for serum isolation. The femur bones
were dissected and divested of soft tissue for analysis of tra-
becular microarchitecture.
Analysis of serum bone biomarkers
Serum calcium (Ca) and phosphorus (P) were measured
as previously described [21]. The serum concentrations
of osteocalcin (OCN) and alkaline phosphatase (ALP)
activity were assayed using an ELISA kit (Biomedical
Technologies Inc., Stoughton, MA, USA) and QuantiChrome
ALP assay kit (DALP-250, BioAssay Systems, CA, USA)
according to the manufacturer’s instructions, respectively.
The serum levels of C-terminal telopeptides (CTx), bone
resorption biomarkers that indicate osteoclastic activity,
were also analyzed using commercial ELISA kits (Serum
CrossLaps, Nordic Bioscience, Herlev, Denmark). The
tartrate-resistant acid phosphatase (TRAP) concentration
was determined by a mouse TRAP assay kit (Suomen
Bioanalytikka Oy, Turku, Finland).
Analysis of bone microarchitecture
Bone microarchitecture of the femur was scanned using a
micro-computed tomography (μCT system, SkyScan 1076,
Aart-selaar, Belgium) in the region of 0.6–2.1 mm from
the growth plate. The X-ray source was set at a voltage of
50 kV and a current of 200 μA and filtered with a 0.5 mm
aluminum filter. The scanning angular rotation was 180°
with an angular step of 0.5°. The voxel size was fixed at
8.9 μm. The morphometric index of the bone region was
determined from the microtomographic data using a 3D
image (SkyScan). The following measures characterizing
the three-dimensional structure of a trabecular bone were
determined: the ratio of bone components to volume of
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becular separation (Tb.Sp, mm), trabecular bone number
(Tb.N, mm-1), and structure model index (SMI).
BV/TV indicates the ratio which a trabecular bone is
occupied with a given volume of interest, usually mea-
sured as a% value. Tb.Th and Tb.Sp define the shape of
a trabecular bone, whereas Tb.N implies the number of
traversals made per unit length on a random linear path
across a trabecular bone through a given volume of inter-
est. SMI quantifies the relative prevalence of rod-, plate-,
or sphere-shapes in a trabecular bone structure.
Chemicals
α-Modified minimal essential medium (α-MEM), fetal bo-
vine serum (FBS), sodium pyruvate, L-glutamine, antibiotic-
antimycotic solution, and trypsin-EDTA were purchased
from Invitrogen Co. (Grand Island, NY, USA). RANKL
and macrophage-colony stimulating factor (M-CSF) were
purchased from R&D systems (Minneapolis, MN, USA). As-
corbic acid, β-glycerophosphate,3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), and other chemicals
were obtained from Sigma (St. Louis, MO, USA) unless
otherwise indicated.
Cell culture
Mouse calvaria MC3T3-E1 cells, obtained from American
Type Culture Collection (ATCC, Rockville, MD, USA),
were cultured in α-MEM supplemented with 10% heat-
inactivated FBS, 100 units/mL penicillin, 100 μg/mL
streptomycin, and 0.25 μg/mL amphotericin B. Cells
were incubated at 37°C and 5% CO2 in a humidified
atmosphere.
Evaluation of growth inhibitory potential
MC3T3-E1 cells (1 × 104 cells/mL in 96-well plates)
were treated with various concentrations of JSOG-6
and incubated at 37°C in a humidified atmosphere with
5% CO2. After JSOG-6 treatment for 72 h, MTT solu-
tion (5 mg/mL in PBS) was added to the medium (final
concentration 500 μg/mL) and further incubated for
4 h. The medium was discarded and 200 μL of (100% or
10%) DMSO was added to each well to dissolve the for-
mazan. The absorbance was measured at 570 nm. The
effect of JSOG-6 on cell growth was calculated as a per-
centage relative to solvent-treated control incubations,
and the IC50 values were calculated using non-linear
regression analysis (percent cell proliferation versus
concentration).
Alkaline phosphatase (ALP) activity
The ALP activity was determined according to a previ-
ously described method [22]. MC3T3-E1 cells were in-
cubated in osteogenic medium containing 400 μM
ascorbic acid and 5 mM β-glycerophosphate. The cells(2 × 104 cells/mL) were incubated with or without vari-
ous concentrations of JSOG-6. After 4 days, the cells
were washed with PBS and fixed with 70% ethanol for
5 min and then extracted into lysis solution (10 mM Tris,
0.1% Triton X-100 buffer (pH 7.5). Enzyme activity was
determined using p-nitrophenylphosphate (p-NPP) as a
substrate. The color change reflecting the conversion of p-
NPP to p-nitrophenol was measured at 405 nm. The pro-
tein concentration of cell lysates was measured using the
Bradford assay.Mineralization assay
The calcium deposition of MC3T3-E1 cells was deter-
mined by a previously reported method [23]. MC3T3-
E1 cells (2 × 104 cells/mL) were incubated with or
without various concentrations of JSOG-6 for 14 days.
The cells were washed twice with PBS and fixed with
70% ethanol for 30 min. The fixed MC3T3-E1 cells
were stained with 2% Alizarin Red S solution (pH 4.0)
for 5 min. The plate was washed several times by dis-
tilled water, and then the cells were observed under a
microscope.Real-time reverse transcriptase-polymerase chain reaction
(Real-time RT-PCR)
Lipopolysaccharide (LPS), a cell component of Gram-
negative bacteria, is an important mediator of pathological
bone destruction associated with inflammation. MC3T3-
E1 cells were stimulated with 1 μg/mL LPS in the presence
or absence of JSOG-6 for 48 h. Total cellular RNA was
extracted with TRI reagent (Sigma, St. Louis, MO, USA)
according to the manufacturer’s recommended procedure.
Total RNA (1 μg) was reverse-transcribed using oligo-(dT)15
primers and avian myeloblastosis virus (AMV) reverse tran-
scriptase (Promega, Madison, WI, USA).
Real-time RT-PCR was conducted with a MiniOpti-
con system (Bio-Rad, Hercules, CA, USA) using 5 μL
of the reverse-transcription product, iQ™ SYBR® Green
Supermix (Bio-Rad, Hercules, CA, USA) and primers
for a total volume of 20 μL. Standard thermal cycler
conditions were employed (95°C for 20 s, 40 cycles of
95°C for 20 s, 56°C for 20 s, and 72°C for 30 s, followed
by 95°C for 1 min, and 55°C for 1 min). The threshold
cycle (CT), the fractional cycle number at which the
amount of amplified target gene reaches a fixed thresh-
old, was determined by MJ Opticon Monitor software.
The mean threshold cycle (CT) value for each transcript
was normalized by dividing it by the mean CT value for
the β-actin transcript for that sample. Normalized tran-
script levels were expressed relative to those obtained
from the control. Real-time RT-PCR primer sequences
are listed in Table 1.
Table 1 Sequences of target gene-specific primers used in real-time PCR
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MC3T3-E1 cells (5 × 105 cells/mL in 60 mm dish)
were incubated with or without various concentra-
tions of JSOG-6 for 48 h. To obtain total cell lysates,
the cells were washed with ice-cold PBS and lysed in
boiling 2X sample loading buffer (250 mM Tris–HClFigure 1 Effect of JSOG-6 on bone loss in OVX mice. (A) Change in bo
microCT image of the distal femur in OVX mice. (C) Effect of JSOG-6 on the
as analyzed with micro-CT SkyScan CTAN software. Data represent the mea
from the OVX mice group.(pH 6.8), 4% SDS, 10% glycerol, 0.006% bromophenol
blue, 50 mM sodium fluoride, 5 mM sodium orthova-
nadate, and 2% β-mercaptoethanol). Cell lysates were
boiled for an additional 20 min and stored at −20°C.
The protein content of cell lysates was determined by
the BCA method.dy weight 12 weeks after ovarietomy. (B) Effect of JSOG-6 on bone 3D
bone morphometric parameters BMD, BV/TV (%), and Tb.No (1/mm)
n ± S.D. (n = 8). *P < 0.01 indicates statistically significant differences
Table 2 Effect of JSOG-6 on the serum parameters in OVX mice
Calcium concentration Potassium concentration ALP activity TRAP activity Osteocalcin level CTx level
Sham 9.1 ± 0.4 8.0 ± 0.3 67.6 ± 2.8 9.1 ± 0.9 148.9 ± 5.3 69.5 ± 4.3
OVX 9.3 ± 0.3 8.3 ± 0.4 85.0 ± 3.1 19.8 ± 1.0 176.9 ± 4.7 95.7 ± 3.8
E2 9.1 ± 0.6 7.9 ± 0.2 59.9 ± 3.1* 10.8 ± 1.0* 141.9 ± 4.9* 76.6 ± 4.7*
JSOG-6
50 mg/kg 9.4 ± 0.5 7.9 ± 0.3 59.3 ± 3.8* 11.6 ± 1.4* 165.0 ± 6.6 92.3 ± 3.6
150 mg/kg 9.4 ± 0.6 7.9 ± 0.3 62.8 ± 4.6* 9.7 ± 1.1* 155.8 ± 5.1* 89.7 ± 5.2
450 mg/kg 9.6 ± 0.4 8.1 ± 0.4 65.9 ± 3.4* 8.3 ± 0.7* 153.0 ± 5.3* 83.6 ± 3.8*
The serum levels of calcium, potassium, ALP, CTx, OCN, and TARP were analyzed as described in the Methods. Data represent the mean ± S.D. (n = 8). *P < 0.01
indicates statistically significant differences from the OVX mice group.
Figure 2 Effect of JSOG-6 on ALP activity in MC3T3-E1 cells. (A) Cell viability was measured by the MTT method as described in the
Methods. (B) MC3T3-E1 cells (2 × 104 cells/mL) were incubated with JSOG-6 in the presence of ascorbic acid and β-glycerophosphate for 4 days.
The ALP activity was corrected for the amount of protein. Data represent the mean ± S.D. (n = 3). *P < 0.05, **P < 0.01 indicates statistically
significant differences from the control group. N.C., negative control; P.C., positive control (ascorbic acid + β-glycerophosphate).
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Equal amounts of cell lysates (40 ~ 50 μg) were subjected
to 8% and 10% SDS-PAGE and electrotransferred onto
polyvinylidene difluoride (PVDF) membranes (Millipore,
MA, USA). Membranes were blocked in PBST (PBS with
0.1% Tween-20) containing 5% non-fat dry milk for 1 h at
room temperature. After washing 3 times with PBST,
membranes were incubated with primary antibodies
against OPG, RANKL, c-Fos, and TRAF6 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), p-ERK, ERK (Cell
Signaling, Danvers, MA, USA), and β-actin (Sigma) for
3 h at room temperature or overnight at 4°C. Membranes
were washed 3 times with PBST and incubated with the
corresponding secondary antibodies (Santa Cruz) for
90 min at room temperature. The blots were washed 3
times with PBST and visualized using an enhanced
chemiluminescence (ECL) Western blotting detection
system (Lab Frontier, Suwon, Korea).
Murine bone marrow-derived osteoclasts
BMCs were isolated from 4-week-old mice as previously
described [24]. The cells were plated into 96-well plates
in 30 ng/mL of M-CSF for 24 h. Next, the cells were
treated with the indicated concentrations of JSOG-6 in
the presence of 100 ng/mL of RANKL and 30 ng/mL ofFigure 3 Effect of JSOG-6 on the mineralization of MC3T3-E1 cells.
the presence of ascorbic acid and β-glycerophosphate for 14 days. Mine
Data represent the mean ± S.D. (n = 3). *P < 0.01 indicates statistically sig
microscopic observation of JSOG-6 on the formation of calcification nod
control (ascorbic acid + β-glycerophosphate).M-CSF. The medium was replaced with 50% volume
with and without JSOG-6 every 2 days, and the culture
was terminated after 5 days.Tartrate-resistant acid phosphatase (TRAP) staining
Osteoclast differentiation was assessed by TRAP (Sigma-
Aldrich, St. Louis, MO, USA) activity. 5 days after stimulat-
ing the cells with M-CSF and RANKL (100 and 30 ng/mL,
respectively), the cells were washed with PBS and fixed with
4% paraformaldehyde for 5 min. The cells were rinsed in
de-ionized water and incubated in tartrate-staining solution
in the dark for 1 h at 37°C. The cells were rinsed in de-
ionized water and allowed to air dry. TRAP-positive multi-
nucleated cells containing 3 or more nuclei were counted
as osteoclasts.Statistics
All experiments were repeated at least 3 times. Data
are presented as the mean ± SD for the indicated num-
ber of independently performed experiments. The statis-
tical significance within a parameter was evaluated by
one-way analysis of variation (ANOVA) coupled with
Dunnett’s t-test.(A) MC3T3-E1 cells (2 × 104 cells/mL) were incubated with JSOG-6 in
ralized nodule formation was assessed by Alizarin red S staining.
nificant differences from the control group. (B) Representative
ules with staining Alizarin red S. N.C., negative control; P.C., positive
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Effect of JSOG-6 on bone loss in an OVX-induced
mouse model
The anti-osteoporotic activity of JSOG-6 was primarily per-
formed in an in vivo experiment employing an OVX-
induced bone loss mouse model. Body weight change was
monitored during the administration of JSOG-6. As shown
in Figure 1A, the increase in body weight in the OVX
group was significantly higher than that in the Sham-
operation group (P < 0.01). However, mice given an oral ad-
ministration of JSOG-6 for 12 weeks after OVX showed a
relatively slow increase in body weight compared to the
OVX group. The estradiol (E2, 10 μg/kg)-treated group
showed a similar result. The destruction of the trabecular
bone of the femur was also observed by 3D-μCT. As illus-
trated in Figure 1B, OVX caused a significant deterioration
of trabecular bone architecture compared with the Sham-
control group (P < 0.01). However, treatment with JSOG-6
retarded or recovered the destruction of the trabecular
bone of the femur in a dose-dependent manner in the
OVX-induced bone loss model. The protective effect on
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Figure 4 Effect of JSOG-6 on osteoblastic gene expression. MC3T3-E1
of JSOG-6 for 48 h, and the mRNA levels of osteoblastic genes were exami
level compared to unstimulated cells and were normalized to β-actin. Data repr
significant differences from the control group.demonstrated by treatment with E2, a positive control,
in the same experimental condition. In addition, the
microstructural index parameters were observed in the
OVX-induced bone loss model (Figure 1C). The BMD
of the OVX group was markedly reduced by 38.7% in
comparison with the Sham group. The BMD of the tra-
becular bone of the femur in mice treated with JSOG-6
(50 mg/kg) was shown to be 83.0% higher than that in
the OVX group and was not significantly different from
that in the Sham control group (P < 0.01). E2 also in-
creased the BMD by 80.9% in the OVX-induced bone
loss mouse model. The BV/TV was also markedly re-
duced in the OVX group (64.7%) compared with the Sham
group, but the treatment of OVX mice with JSOG-6 or E2
resulted in a significant increase in the BV/TV in the
OVX-induced bone loss model (P < 0.01). The Tb.No in
the OVX group was 63.8% lower than that of the Sham
group, but JSOG-6 treatment (50, 150, and 450 mg/kg)
significantly recovered the Tb.No value to 113.3, 145.6,
and 192.2%, respectively, in a dose-dependent manner
than the OVX group. The E2-treated group also showed a
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cells (2 × 104 cells/mL) were treated with the indicated concentrations
ned using real-time PCR. The results are presented as a relative expression
esent the mean ± S.D. (n = 3). *P< 0.05, **P< 0.01 indicates statistically
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OVX mouse model
The effects of JSOG-6 on the bone metabolic bio-
markers were also determined with the serum of blood
samples collected in OVX mice. The serum levels of cal-
cium and potassium were not significantly different in
the Sham, JSOG-6 treatment, and OVX groups (P <
0.01) (Table 2). The serum levels of the bone formation
markers ALP and OCN were significantly increased in
the OVX group compared to the Sham group. However,
JSOG-6 treatment decreased the elevated serum levels of
ALP and OCN in the OVX mice (P < 0.01). In addition, the
serum level of TRAP, which is responsible for enhanced os-
teoclastogenesis and activation of mature osteoclasts for
bone resorption, was increased in the OVX group, but
JSOG-6 treatment significantly reduced TRAP activity in a
dose-dependent manner (P < 0.01). The increase in an add-
itional bone resorption marker, CTx, in the OVX group
was also inhibited by JSOG-6 treatment (P < 0.01) (Table 2).
Effect of JSOG-6 on the ALP activity of MC3T3-E1 cells
The ALP staining activity, a marker of osteoblastic differ-
entiation [25,26], was evaluated in osteoblastic MC3T3-El
cells. There was no effect on MC3T3-El cell viability with
JSOG-6 treatment up to 100 μg/mL as determined by the
MTT assay (>95% cell viability) (Figure 2A). Therefore,
the cells were treated with up to 100 μg/mL JSOG-6 to
understand the biological effects of JSOG-6 without caus-
ing cytotoxicity. The MC3T3-El cells were differentiated
in the presence of ascorbic acid and β-glycerophosphate in
the cell culture medium. After 4 days of differentiation,
JSOG-6 was found to enhance the density and ALP activ-
ity in a concentration-dependent manner (Figure 2B).
Effect of JSOG-6 on the mineralization of MC3T3-E1 cells
Extracellular matrix mineralization is one of the markers of
osteoblastic maturation. Alizarins red S staining was used
to evaluate extracellular matrix calcium deposition. As illus-
trated in Figure 3, when the cells were simultaneously
treated with JSOG-6 for 14 days, the calcification nodules,
represented in red, in MC3T3-E1 cells were increased in a
concentration-dependent manner. These results indicate
that the effect of JSOG-6 on the ALP activity and calcium
deposition stimulated osteoblast differentiation.Figure 5 Effect of JSOG-6 on the protein levels of OPG, RANKL,
and ERK in MC3T3-E1 cells. (A, B) MC3T3-E1 cells (2× 104 cells/mL)
were incubated for 48 h and then treated with JSOG-6 for 48 h. After
incubation, total cell extracts were obtained and subjected to Western
blot analysis as described in the Methods. Data were representative of
three separate experiments. β-Actin was used as an internal standard.Effect of JSOG-6 on osteoblastic gene expression
The effects of JSOG-6 on osteoblast differentiation was fur-
ther elucidated using the analysis of expression of osteo-
genic differentiation mediators mRNA by real-time RT-
PCR. After 2 days of differentiation, JSOG-6 (100 μg/mL)
caused a significant (P < 0.01) increase in the expressions of
ALP and OPN mRNA, whereas the expression of OCN
mRNA was decreased by JSOG-6 treatment. OPG andRANKL play important roles in the maintenance of bone
mass and the regulation of bone remodeling. The OPG/
RANKL ratio is the major index of osteoclastogenic stimu-
lation. JSOG-6 treatment induced the expression of OPG
mRNA in a concentration-dependent manner, whereas
JSOG-6 significantly suppressed the expression of RANKL
mRNA (*P < 0.05, **P < 0.01). In addition, JSOG-6 signifi-
cantly increased the OPG/RANKL ratio in MC3T3-E1 cells
(*P < 0.01) (Figure 4). These findings suggest that JSOG-6
might modulate the process of osteoclastogenesis via its ef-
fect on the OPG/RANKL gene expressions.Effect of JSOG-6 on the protein levels of OPG, RANKL, and
ERK in MC3T3-E1 cells
The effect of JSOG-6 on the protein expressions of OPG,
RANKL, and ERK in MC3T3-E1 cells was evaluated to con-
firm the activity of JSOG-6 on osteogenic differentiation. As
shown in Figure 5A, JSOG-6 increased the protein expres-
sion of OPG in a concentration-dependent manner, but
the protein expression of RANKL was suppressed. In
addition, JSOG-6 treatment induced ERK phosphorylation
(Figure 5B).
Figure 6 Effect of JSOG-6 on RANKL-induced osteoclast differentiation. (A) Cell viability was measured by the MTT method as described in
the Methods. (B) Bone marrow cells (1 × 104 cells/mL) were incubated with JSOG-6 in the presence of M-CSF (30 ng/mL) and RANKL (100 ng/mL)
for 5 days. Osteoclastogenesis was confirmed by TRAP staining. Data represent the mean ± S.D. (n = 3). **P < 0.01 indicates statistically significant
differences from the control group. (C) The expression of TRAP was determined by Western blot analysis as described in the Methods. Data are
representative of three separated experiments. β-Actin was used as an internal standard.
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TRAP staining was performed to evaluate the effect of
JSOG-6 on RANKL-induced osteoclast differentiation. As
depicted in Figure 6A, no cytotoxic effect on BMCs was ob-
served at a test concentration up to 100 μg/mL JSOG-6 as
determined by the MTT assay (>85% cell survival rate).
BMCs were allowed to differentiate into osteoclasts in the
presence of RANKL and M-CSF for 5 days. JSOG-6
inhibited the formation of TRAP-positive cells during
RANKL-induced osteoclast differentiation in a concentration-
dependent manner (Figure 6B). Western blot analysis showed
that JSOG-6 also suppressed the protein expression of
TRAF6 in RANKL-stimulated cells (Figure 6C).
Discussion
Osteoporosis is an age-dependent skeletal metabolic dis-
ease in which patients suffer from lower bone density
and lower bone mass compared to healthy individuals
[27,28]. The disease is also associated with a homeostatic
imbalance between bone modeling and bone resorption.
Although the main cause of the disease is not clear, en-
docrinologic, nutritional, and genetic factors are thought
to be highly involved in osteoporosis.JSOG-6 is an herbal preparation derived from six trad-
itional medicines that have been clinically used to treat
inflammation-associated diseases in oriental Korean medi-
cine. However, the exact pharmacological effect and its
underlying mechanisms of action remain to be elucidated.
Therefore, the present study was performed to investigate
the anti-osteoporotic activity of JSOG-6 in an OVX mouse
model and to further elucidate its underlying mechanisms
of actions both in vitro and in vivo.
The OVX animal model has been widely used to study
postmenopausal osteoporosis mimicked by estrogen in-
sufficiency [29,30]. Deterioration of trabecular 3D micro-
architecture is apparent in the OVX mouse model [31].
We found that JSOG-6 prevented the deterioration of
microstructural parameters in the distal femur in mice.
Oral administration of JSOG-6 restored bone loss back
in OVX mice (Figure 1). These results indicated that
JSOG-6 was effective not only in preserving bone mass
but also in rescuing the deterioration of bone microarch-
itecture associated with OVX mice.
Biochemical markers of bone turnover have been deter-
mined previously, allowing the evaluation of the status of
bone remodeling [32]. Analyses of the serum levels of ALP
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CTx and TRAP, biomarkers of bone resorption, showed
that the serum concentrations of ALP, OCN, CTx and
TRAP in OVX mice were significantly higher than those
in the Sham group. However, the levels of ALP and
TRAP in the JSOG-6-treated group were equivalent to
the levels in the Sham group (Table 2). These data sug-
gest that JSOG-6 most likely prevents bone loss through
decreased bone turnover.
In addition, the mechanisms underlying the cellular
effects of JSOG-6 were investigated in osteoblasts and oste-
oclasts. Osteoblasts, bone-forming cells, synthesize and
regulate the deposition and mineralization of the extracellu-
lar matrix of bone [33,34]. In this study, JSOG-6 treatment
was found to increase the ALP activity in a concentration-
dependent manner in MC3T3-E1 cells (Figure 2). JSOG-6
also led to an increase of calcium deposition in MC3T3- E1
cells (Figure 3).
To further explore the mechanism responsible for the ef-
fect of JSOG-6 on the regulation of osteoblasts, the markers
of bone formation in MC3T3-E1 cells were detected by
real-time RT-PCR. LPS leads to the intracellular induction
of p38, JNK phosphorylation, and NFκB in macrophages
and monocytes, and promotes the differentiation and sur-
vival of osteoclasts through the production of several fac-
tors such as PGE2, interleukin 1, RANKL, and TNF [35].
The levels of the bone formation biomarkers ALP, OPN,
and OPG/RANKL mRNAs were up-regulated by JSOG-6
treatment (Figure 4).
RANKL drives osteoclastogenesis by providing an
important signal to osteoclast progenitors through the
membrane-anchored receptor RANK in osteoclasts. Oste-
oblasts also synthesize and secrete OPG, a decoy receptor
of RANKL, which blocks the interaction between RANKL
and RANK. Therefore, the expression of OPG/RANKL
plays an essential role in modulating bone remodeling
[36,37]. OPG was also able to block the interaction of
RANKL with osteoclast cells, thus suppressing osteoclas-
togenesis [38]. The data showed that JSOG-6 up-regulated
the protein expression of OPG and down-regulated that of
RANKL (Figure 5A). Therefore, the suppression of the
protein expressions of OPG and RANKL by JSOG-6 might
be a plausible partial mechanism of action of its modula-
tion of bone remodeling.
Various intracellular signaling pathways are involved in
the regulation of osteoblast differentiation. ERK is consid-
ered to be an essential function in the proliferation and
differentiation of osteoblasts [39,40]. In this study, JSOG-6
treatment induced the activation of ERK (Figure 5). These
findings also suggest that JSOG-6 might have potential in
improving bone formation.
Bone formation is regulated by crosstalk between bone-
forming osteoblasts and bone-resorbing osteoclasts. Unbal-
anced osteoclastogenesis causes bone loss in osteoporosis[41,42]. M-CSF and RANKL are important cytokines that
cause osteoclast precursors to differentiate into activated
osteoclasts [43]. The present study showed that JSOG-6
suppressed RANKL-induced differentiation of osteoclasts
by down-regulating the protein expression of TRAF6 in
BMCs (Figure 6). These in vitro findings were well corre-
lated with the in vivo anti-osteoporotic effects of JSOG-6,
and thus JSOG-6 might be applicable to the clinic for im-
proving age-dependent bone destruction disease.
Conclusions
The present study provides evidence that JSOG-6 has a po-
tential anti-osteoporotic activity both in vitro and in vivo.
The underlying mechanisms of action of JSOG-6 are corre-
lated with the induction of ALP activation in osteoblasts,
the increase in calcified bone matrix, and the reduction of
osteoclast formation. These data provide a pharmaco-
logical basis for the use of JSOG-6 as a potential thera-
peutic strategy for protecting against osteoporotic bone
loss in clinic.
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